Biotech Values

[pharmaclown35]

how come all the news services, bloomberg, reuters, others were all positive on cladribine data after AAN? all the headlines said first oral MS drug to market?

is there a disconnect there?

I think NVS FTY720 will probably make it to market first.

Campath also reported excellent efficacy data at AAN. company is running a risk management program. I think they all should run REMS programs.